MSME (Udyam registered) Ministry of MSME
- Category
- Small (2024-25)
- Udyam number
- UDYAM-TN-02-0095765
Unilink Pharma Private Limited - pharma in Chennai, Tamil Nadu, India. FY 2026 financials & compliance.
Revenue · FY 2024
₹52.34 Cr
▼ 18% YoY
Net profit · FY 2024
₹1.31 Cr
Net margin 2.5%
EBITDA · FY 2024
₹4.7 Cr
EBITDA margin 9%
Authorised capital
₹3 Cr
Registered with MCA
Paid-up capital
₹1.6 Cr
Issued & subscribed
Open charges
₹23.53 Cr
Secured borrowings
Company age
21 yrs
Est. 2005
Directors on board
2
As per MCA filings
About Unilink Pharma Private Limited
Data last updated:
Unilink Pharma Private Limited is a private limited company based in Chennai, Tamil Nadu, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 23 February 2005 and has been in existence for over 21 years.
The company is registered with the Registrar of Companies (ROC), Chennai, under CIN U24232TN2005PTC055459. Its GSTIN is 33AAACU7368Q1ZN (Tamil Nadu).
The company has an authorised share capital of ₹3 Cr and a paid-up capital of ₹1.6 Cr. It was formerly known as Unilink Drugs and Pharmaceuticals Private Limited. It is led by directors Karunakaran Vijaya (Managing Director) and Sreenivasan Karunakaran (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at New No.111 Old No.23 Parthasarathypuram T Nagar, Chennai, Tamil Nadu, India – 600017.
As per the financials filed for FY 2024, the company reported a revenue of ₹52.34 Cr, a decline of 18% compared to the previous year. For the same year it recorded a net profit of ₹1.31 Cr (net margin 2.5%) and EBITDA of ₹4.7 Cr (EBITDA margin 9%). Revenue has grown at a compounded annual rate (CAGR) of 6% over three years and 2% over five years.
The company is associated with 1 brand: Unilink Pharma. As per MCA filings, the company has open charges of ₹23.53 Cr on record. Court records list 15 cases involving the company, including 13 filed by the company and 2 filed against it.
Unilink Pharma Private Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-TN-02-0095765). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website unilinkpharma.com.
Company details
CIN U24232TN2005PTC055459
Registration Number 055459
Incorporation Date 23 February 2005
ROC Chennai
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-TN-02-0095765
Recognitions & Rankings of Unilink Pharma
Contact details
Unilink Pharma Private Limited's registered office is in Chennai, Tamil Nadu. Its website is unilinkpharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressNew No.111 Old No.23 Parthasarathypuram T Nagar, Chennai, Tamil Nadu, India – 600017
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Unilink Pharma Private Limited, buy the company report.
Comprehensive company report
Unilink Pharma Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Unilink Pharma operates one associated brand: Unilink Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical manufacturing and exporting of generic medicines and supplements are conducted. | unilinkpharma.com |
Business activity
The main business activity of Unilink Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Unilink Pharma Private Limited, buy the company report.
Financials of Unilink Pharma Private Limited
FY 2025 filings availableUnilink Pharma Private Limited reported revenue of ₹52.34 Cr (down 18% YoY) for FY 2024.
Revenue · FY 2024
₹52.34 Cr ▼ 18%
Net profit · FY 2024
₹1.31 Cr margin 2.5%
EBITDA · FY 2024
₹4.7 Cr margin 9%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▼ 18%
3 years · compounded
▼ 6%
5 years · compounded
▲ 2%
EBITDA CAGR growth
1 year
▼ 26%
3 years · compounded
▼ 19%
5 years · compounded
▼ 4%
Revenue fell 18% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 2%. EBITDA fell 26% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹4.7 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹1.31 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 9% | ||||
| Net Profit Margin | 2.5% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Unilink Pharma Private Limited, buy the company report.
Board of directors of Unilink Pharma Private Limited
Unilink Pharma has 2 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sreenivasan Karunakaran | Whole-Time Director | 02 Oct 2009 | 17 Years 0 Months | Current |
| Karunakaran Vijaya | Managing Director | 23 Feb 2005 | 21 Years 8 Months | Current |
Peer comparison
Unilink Pharma Private Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Vardhaman Remedies Private Limited | ₹53.36 Cr (FY 2025) | 14.0% | Mumbai, Maharashtra, India | |||
| Pharma Synth Formulations Limited | ₹53.06 Cr (FY 2024) | 1.0% | Delhi, India | |||
| Prerana Agrochem Private Limited | ₹52.43 Cr (FY 2025) | 253.0% | Bharuch, Gujarat, India | |||
| Unilink Pharma Private Limitedthis company | ₹52.34 Cr (FY 2024) | ₹1.31 Cr | 2.5% | -18.0% | Chennai, Tamil Nadu, India | |
| Therallen Pharma Private Limited | ₹52.29 Cr (FY 2025) | 34.0% | Hyderabad, Telangana, India | |||
| Intracin Pharmaceuticals Private Limited | ₹52.07 Cr (FY 2024) | 39.0% | Nadiad, Gujarat, India | |||
| Srivathsa Lifesciences Private Limited | ₹51.99 Cr (FY 2024) | 25.0% | Hyderabad, Telangana, India | |||
| Ranq Pharmaceuticals and Excipients Private Limited | ₹51.83 Cr (FY 2025) | 5.0% | Thane, Maharashtra, India | |||
| Smayan Healthcare Private Limited | ₹51.72 Cr (FY 2024) | 19.0% | Chandigarh, India |
To see the full peer comparison of Unilink Pharma Private Limited, buy the company report.
Auditor
Unilink Pharma Private Limited is audited by HARI & NARAYANAN for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| HARI & NARAYANAN | FY 2023 | 04885S |
Shareholding
The shareholding of Unilink Pharma Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Unilink Pharma Private Limited, buy the company report.
Charges & borrowings
Open charges
₹23.53 Cr
Satisfied charges
None
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 30 May 2020 | 100367338 | State Bank of India | ₹1.97 Cr | Open | |
| 08 Jan 2020 | 100313511 | Others | ₹3 Cr | Open | |
| 19 Mar 2014 | 10485266 | Icici Bank Limited | ₹1.4 Cr | Open | |
| 01 Oct 2009 | 10179354 | Icici Home Finance Company Limited | ₹1.24 Cr | Open | |
| 28 Mar 2005 | 80020355 | State Bank of India | ₹15.92 Cr | Open |
To see the full charge records of Unilink Pharma Private Limited, buy the company report.
Total charge records: 5 View all charges
Legal cases
Unilink Pharma Private Limited has 15 court cases on record: 13 filed by Unilink Pharma, 2 filed against it. All cases are disposed.
Total cases
15
Filed by the company
13
Filed against the company
2
Disposed
15
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 13 | 0 | 0 |
| District courts | 2 | 2 | 0 |
Cases on record (5 of 15)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Vadodara, Gujarat | Court case (TMSUIT) | Filed against the company by GB Pharma Limited and 1 other | Disposed |
| Madras High Court | Writ petition | Filed by the company against an individual | Disposed |
| Madras High Court | Interim or miscellaneous application | Filed by the company against an individual | Disposed |
| High Court, TAMIL NADU | Writ petition | Filed by the company against The Union of India and 4 others | Disposed |
| District court, Chennai, Tamil Nadu | Civil suit | Filed against the company by an individual | Disposed |
To see the full case history of Unilink Pharma Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Unilink Pharma Private Limited has 8 MSME Form 1 returns on record between 2019 and 2023, listing 83 overdue payments to 20 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 20)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Sri Vaishnavi Graphics Private Limited | |||
| Corel Pharma | |||
| an individual supplier | |||
| Daga Poly Laminators Private Limited | |||
| an individual supplier |
To see the full MSME payment records of Unilink Pharma Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
GST
Unilink Pharma has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 33AAACU7368Q1ZN | Tamil Nadu | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Unilink Pharma Private Limited, buy the company report.
Recent activity
Unilink Pharma Private Limited has 8 board changes on record since 2005: 2 appointments and 6 cessations. The latest: Tpalanisamy ceased to be Director on 06 Dec 2021.
AGM
Unilink Pharma Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Unilink Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Chennai.
Charges
A charge with State Bank Of India of Rs. 15.92 Cr registered on 28 Mar 2005 with Charge ID 80020355 was modified on 26 Mar 2024.
Ceased
Tpalanisamy ceased to be Director.
Charges
A charge with State Bank Of India amounted to Rs. 1.97 Cr with Charge ID 100367338 was registered on 30 May 2020.
Charges
A charge with Others amounted to Rs. 3.00 Cr with Charge ID 100313511 was registered on 08 Jan 2020.
Ceased
Sreenivasan Karunakaran ceased to be Director.
Ceased
Karunakaran Vijaya ceased to be Managing Director.
Ceased
Donapadmanabha Venkatesan ceased to be Director.
Charges
A charge with Icici Bank Limited amounted to Rs. 1.40 Cr with Charge ID 10485266 was registered on 19 Mar 2014.
Appointed
Sreenivasan Karunakaran was appointed as Whole-Time Director.
Charges
A charge with Icici Home Finance Company Limited amounted to Rs. 1.24 Cr with Charge ID 10179354 was registered on 01 Oct 2009.
5 earlier events are in the company report.
Frequently asked questions
Unilink Pharma is an active private limited company based in Chennai, Tamil Nadu, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 23 February 2005 (21+ years old) and is registered under CIN U24232TN2005PTC055459.
Unilink Pharma has 2 current directors:
- Karunakaran Vijaya - Managing Director
- Sreenivasan Karunakaran - Whole-Time Director
The latest financial statements of Unilink Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Unilink Pharma is 33AAACU7368Q1ZN, registered in Tamil Nadu.
The CIN (Corporate Identification Number) of Unilink Pharma is U24232TN2005PTC055459. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Unilink Pharma has 15 court cases on record: 13 filed by the company and 2 filed against it. Most are in the high courts.
Unilink Pharma was incorporated on 23 February 2005, making it 21+ years old. It is registered with the Registrar of Companies, Chennai.
The peers of Unilink Pharma by revenue are Vardhaman Remedies Private Limited, Pharma Synth Formulations Limited, Prerana Agrochem Private Limited, Therallen Pharma Private Limited, Intracin Pharmaceuticals Private Limited and 3 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Tpalanisamy ceased to be Director on 06 Dec 2021. Sreenivasan Karunakaran ceased to be Director on 01 Apr 2019. Karunakaran Vijaya ceased to be Managing Director on 31 Mar 2019. Unilink Pharma has 8 board changes on record in total.
Yes, Unilink Pharma is registered as a small enterprise under Udyam registration (number: UDYAM-TN-02-0095765).
Unilink Pharma has 8 MSME Form 1 returns on record between 2019 and 2023, listing 83 overdue payments to 20 micro and small suppliers. The latest return was filed on 25 Apr 2023.
Unilink Pharma can be reached through the website unilinkpharma.com. Its registered office is in Chennai, Tamil Nadu, India.